IRVINE, Calif.--(BUSINESS WIRE)--Jan. 3, 2006--Allergan, Inc. (NYSE:AGN) announced today that on December 29, 2005, in its patent infringement lawsuit against Apotex, Inc., Apotex Corp., and Novex Pharma (collectively the “Defendants”), the United District Court for the Northern District of California granted Allergan’s and Syntex (USA) LLC’s application for a temporary restraining order against the Defendants. In its ruling, the District Court ordered that the Defendants “are restrained and enjoined, pending the Court’s decision as to whether a preliminary injunction should issue, from commercially manufacturing, using, offering to sell, or selling within the United States or importing into the United States” the generic version of ACULAR(R) (ketorolac tromethamine ophthalmic solution) 0.5% for which the Defendants have sought FDA approval via an abbreviated new drug application.
